NCT00941343

Benign Prostatic Hyperplasia in Taiwan

Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 362 (actual)
• Sponsor: Sanofi · Industry
• Sex: Male
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

Primary Objective: * To assess the sexual function of Benign Prostatic Hyperplasia patients Secondary Objective: * To evaluate the association between Lower Urinary Tract Symptoms severity and sexual disorders * To compare the sexual function, urinary symptoms and Quality of Life of Benign Prostatic Hyperplasia patients on XATRAL 10mg OD among the different regions * To correlate the Male Sexual Health Questionnaire(MSHQ) and 5-item version of the International Index of Erectile Function (IIEF-5) * To assess the onset of action of XATRAL 10mg OD * To assess the peak urinary flow rate * To assess the safety and the tolerability of XATRAL 10mg OD

Conditions

• Prostatic Diseases

Interventions

Type	Name	Description
DRUG	Alfuzosin (XATRAL® - SL770499)	One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed

Timeline

• Start date: 2006-09-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2009-07-17
• Last updated: 2010-03-30

Locations

1 site across 1 country: Taiwan